Clinical Data Rhythm’s obesity drug scores ‘better than expected’ weight loss in rare genetic disease BioSpaceRhythm Pharmaceuticals' Imcivree reduced fat--while boosting muscle--in patients with Prader-Willi syndrome.Rare DiseaseRead full story pharminent June 15, 2026 (Last updated: June 15, 2026) BioSpace Rhythm Pharmaceuticals’ Imcivree reduced fat–while boosting muscle–in patients with Prader-Willi syndrome. Rare Disease Read full story Post navigation Previous: Lilly sees quick return on $2.3B Ajax buy as blood cancer drug shows early efficacyNext: Key pipeline drug for Lundbeck delivers in Cushing syndrome Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026